[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100165257":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":26,"locations":40,"responsibleParty":54,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":79,"whyStopped":80,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"CAMC Health System","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"control group","ACTIVE_COMPARATOR","Dosages of immunosuppressants will be given according to the results of conventional post-transplant lab",[13],"Drug: adjustment of the dosages of immunosuppressants",{"label":15,"type":16,"description":17,"interventionNames":18},"ImmuKnow Study group","EXPERIMENTAL","The dosages of immunosuppressants will be adjusted according to the results of ImmuKnow and conventional post-transplant lab",[19],"Drug: adjustment of immunosuppressant dosages",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","adjustment of immunosuppressant dosages","adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"adjustment of the dosages of immunosuppressants","adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab",[9],[32,36],{"name":33,"affiliation":34,"role":35},"S Jeff Chueh, MD PhD","CAMC Health System, Charleston, WV","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":38,"role":39},"Bashir Sankari, MD","CAMC Health System, Charleston, Wv","STUDY_DIRECTOR",[41],{"facility":42,"status":26,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":26},"CAMC","Charleston","West Virginia","25301","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-81.63262,38.34982,{"lat":52,"lon":51},{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100165257","phase-4-the-role-of-immuknow-in-the-management-of-immunosuppressants-in-the-renal-transplant-patient-100165257",false,"NCT01424345","The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient","A Randomized, Controlled Trial Evaluating the Role of ImmuKnow® in the Management of Immunosuppressants Regarding Opportunistic Infections and Acute Rejection in the Renal Transplant Patient","Inclusion Criteria:\n\n1. De novo kidney transplant patients who are eligible for kidney transplant according to UNOS criteria and agree to participate in the study.\n2. Patients of both sex aged between 18 to 80 years.\n\nExclusion Criteria:\n\n* Any patient with a known immunocompromised disease (e.g. patients with AIDS) or leukocytosis(\\>15,000u\u002FL)","ALL","18 Years","80 Years",{"count":67,"type":68},4,"ACTUAL","INTERVENTIONAL",[71],"PHASE4","The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.",[74],"Kidney Transplant Immunosuppression",[76,77,78],"Kidney Transplantation","Immunosuppression","Immune monitoring","TERMINATED","The PI is relocating to another State\u002F another hospital","2026-03-18",{"date":83,"type":68},"2026-03-20",{"date":85,"type":26},"2011-12",{"date":87,"type":68},"2012-07",{"name":5,"class":6},1]